Genomic Profile and Resistance to Anti-Epidermal Growth Factor Receptor Antibody in RAS-Amplified Colorectal Cancer: A Study Based on a Japanese Cancer Genome Database
RAS amplification is a rare alteration that may confer resistance to anti-EGFR antibodies. Assessing RAS amplification status may help guide the appropriate use of anti-EGFR antibodies in clinical practice.
Authors
- Gota Fujisawa (ORCID: https://orcid.org/0000-0002-0218-200X)
- Yu Miyakawa
- Masahiro Hata (ORCID: https://orcid.org/0000-0002-3836-3515)
- N. Boku
- Yoku Hayakawa (ORCID: https://orcid.org/0000-0002-3988-2499)
- Rei Ishibashi (ORCID: https://orcid.org/0000-0002-9649-6471)
- Takuma Iwata (ORCID: https://orcid.org/0000-0001-5229-3042)
- Kenji Tamada
- Aya Shinozaki-Ushiku
- Mitsuhiro Fujishiro
- Takeshi Hayashi
- Nobumi Suzuki
- Hidenori Kage
Institutions
- Tokyo Medical University (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1200/po-25-00424
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00